Compugen Ltd
CGEN
Market Cap$217.57M
Close$
$2.54
4.6% upside
Current Fair Value
4.6% upsideUndervalued by 4.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $217.57 Million |
|---|---|
| Enterprise Value | $229.22 Million |
| Dividend Yield | $0 (0%) |
| Earnings per Share | $-0.21 |
| Beta | 2.65 |
| Outstanding Shares | 89,535,679 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | 136.07 |
|---|---|
| PEG | -120.47 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 3.83 |
| Enterprise Value to EBIT | 21.67 |
| Enterprise Value to Net Income | 143 |
| Total Debt to Enterprise | 0.08 |
| Debt to Equity | 0.31 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Compugen Ltd
CEO: Anat Cohen-Dayag Compugen is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable, predictive computational discovery platforms to identify novel drug targets and develop therapeutics in the field of cancer immu...